$CTSH

Cognizant (NASDAQ: CTSH) director credited new stock units

Cognizant (CTSH) director Michael Patsalos-Fox received 30.6 deferred restricted stock units and 21.8 restricted stock units, bringing his total holdings to 5,878 and 4,193 units respectively. The deferred units are fully vested and will be settled upon his board service termination, while the restricted units will vest in 2027. No market transactions occurred.

Original reporting
Published Aug 27, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 4:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CTSH
Neutral
high confidence
Mentioned
$CTSH
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CTSHNeutralLow
01

Why it matters

The disclosed awards are routine and unlikely to influence Cognizant's stock price in the short term.

02

Market read

Low relevance; the filing provides a factual update but no actionable trading insight.

03

What to watch

Potential future dilution if many similar grants are issued to other directors.

Relevance 4/10Novelty 3/10Timing: after filing on Aug 25, 2026

Background

Form 4 filings disclose insider transactions; grants of RSUs are common compensation mechanisms for board members.

Company-level read

Ticker impact

$CTSHNeutralHigh confidence
Context

Director Michael Patsalos-Fox was granted 30.5999 deferred RSUs and 21.8273 RSUs on Aug 25, 2026, as disclosed in a Form 4 filing.

Expected impact

minimal to none

Evidence & confidence

Small number of units and zero transaction price indicate no market-moving significance.

Market effects

None; insider grant does not affect the broader IT services sector.

None; limited to Cognizant shareholders.

None

Counterpoint

Even small insider grants can signal confidence; some traders may view it as a subtle bullish cue.

Key entities

  • Michael Patsalos-Fox

    Cognizant board member receiving RSU grants

  • Cognizant Technology Solutions Corp.

    Provider of IT services and consulting

Related articles

$CTSHMedAI 8/10

Cognizant's AI Gamble: What Nearshore Must Learn

Cognizant reported Q2 2026 revenue growth of 4.5%, down from Q2 2025, but beat peers and met guidance. Bookings fell 6% YoY. The company raised full-year EPS guidance to $5.70-$5.82, and its stock surged 41.81% in a month. Cognizant cited AI-led demand and partnerships with Google Cloud and Anthropic.

$CTSHMed

Anthropic Is Only Part of the Story. Cognizant Has a Much Bigger AI Plan.

Cognizant (CTSH) trades at a discount versus its historical valuation, with forward GAAP P/E of 8.31x and P/S of 0.97x. In Q2, it reported EPS $1.37 vs $1.38 expected, 4.5% revenue growth, and $459M free cash flow. Management guided Q3 growth 3.8%-5.3% YoY and FY EPS to $5.76 midpoint. Guggenheim cut its price target to $65 but kept a Buy; analysts’ mean target is $60.12.

$CTSHMedAI 8/10

Cognizant Technology Solutions Corporation Q2 2026 Earnings Call Summary

Cognizant Technology Solutions reported 4.1% year-over-year constant-currency revenue growth in Q2 2026, driven by North America and 12% growth in financial services. The company revised full-year revenue guidance to 4% to 5.5% growth and kept adjusted operating margin at 16% to 16.2%. It cited an $81M one-time India benefit, Project LEAP costs, and interest expense after a $1B Astreya-related draw.

$CTSHMed

Cognizant Earnings: Financial Services and North America Drive Resilient Performance

Morningstar’s stock note says Cognizant (CTSH) reported 4% Q2 constant-currency revenue growth, with operating margin steady at 16% and trailing 12-month bookings up 5%. It attributes results to North America and financial services, where growth was 12%. Morningstar keeps a $84 fair value estimate and 16.0%-16.2% operating margin guidance, while trimming full-year revenue growth outlook to 4.0%-5.5%.